Hepatitis C Caring Ambassadors Program Newsletter
September 2005
In The News
AVI BioPharma Initiates Hepatitis C Clinical Trial
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050928005211&newsLang=en
Quilt Shows Victims of Hepatitis C's Silent Onslaught
http://www.detnews.com/2005/metro/0509/16/B01-317112.htm
Naomi Judd Finds Balance, Purpose in Hepatitis Fight
http://www.azcentral.com/arizonarepublic/arizonaliving/articles/0929qajudd0922.html
Pharmacists Able to Detect 'Hidden' Hepatitis
C in Drug Users [UK]
http://www.prnewswire.co.uk/cgi/news/release?id=154524
Hepatitis C Suit
http://www.wowt.com/news/headlines/1764386.html
Hepatitis C Trial Begins
http://www.fremontneb.com/articles/2005/10/04/news/news1.txt
Budget Lacks Hepatitis C Funds
for Inmates
http://www.lsj.com/apps/pbcs.dll/article?AID=/20051003/NEWS01/510030328/1001/news
http://www.eurekalert.org/pub_releases/2005-10/jws-but100305.php
Hepatitis C Drug Cost-Effective for Anemia
Hepatitis C 'Needn't be a Killer'
http://news.bbc.co.uk/1/hi/health/4293592.stm
Hepatitis C Threatens New Generation of Egyptians
http://www.alertnet.org/thenews/newsdesk/L05168992.htm
Most Chronic Hepatitis C Patients Will Develop Cirrhosis in Later Life
http://www.xagena.it/news/medicinenews_net_news/e17aeca56fab22ce30ac615e72cc64e5.html
Linking MicroRNA to Hepatitis C -Liver-specific microRNA Facilitates Replication of the Virus, Study in Science Shows
http://www.the-scientist.com/news/20050902/01
Sex Abuse Suspect May Have Hepatitis C
http://www.ksl.com/?nid=148&sid=107577
Surgeon Did not Know Locum had Hepatitis C Virus
Flamel Technologies Announces Positive Preliminary Results of a Phase I/II Trial of IFN-alpha-XL in Patients with Chronic Hepatitis C Virus Infection
http://www.leaddiscovery.co.uk/prlink.asp?reclink=http://www.flamel.com/pressReleases/20050923.shtml
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES
Clinical presentation of
chronic hepatitis C in patients with end-stage renal disease and on
hemodialysis versus those with normal renal function.. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16128946&query_hl=108
Serum alpha-fetoprotein
levels in patients with advanced hepatitis C: results from the HALT-C Trial.. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16136646&query_hl=18
High-dose
interferon-alpha2b induction therapy in combination with ribavirin for
treatment of chronic hepatitis C in patients with non-response or relapse after
interferon-alpha monotherapy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16149143&query_hl=18
Hepatitis C is a predictor
of poorer renal survival in diabetic patients. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16123488&query_hl=18
Past excessive alcohol consumption: a major determinant of severe liver
disease among newly referred hepatitis C virus infected patients in hepatology
reference centers, France, 2001. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16117999&query_hl=18
Gamma-glutamyl transferase
(GGT) as an independent predictive factor of sustained virologic response in
patients with hepatitis C treated with interferon-alpha and ribavirin. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16082285&query_hl=18
Liver enzyme values in injection drug users with chronic hepatitis C. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15951255&query_hl=18
Predicting sustained virological responses in chronic hepatitis C patients
treated with peginterferon alfa-2a (40 KD)/ribavirin.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15990196&query_hl=18
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with
pegylated interferon-alpha 2a and ribavirin according to virological response.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108761&query_hl=18
Weight loss during pegylated interferon and ribavirin treatment of chronic
hepatitis C*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108770&query_hl=18
Humoral immune response in
acute hepatitis C virus infection. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16080089&query_hl=18
Higher doses of peginterferon alpha-2b administered twice weekly improve
sustained virological response in difficult-to-treat patients with chronic
hepatitis C: results of a pilot randomized study. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108771&query_hl=18
Hepatitis C virus infection facilitates gallstone formation. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16105130&query_hl=18
Rationale and design of the REPEAT study: a phase III, randomized, clinical
trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to
peginterferon alfa-2b (12 kDa) plus ribavirin. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16093865&query_hl=18
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus
genotype 4 infection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16032749&query_hl=18
Antiviral activity and
safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in
HIV-infected adults.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16135896&query_hl=18
Basic and Applied Science, Pre-Clinical Studies
Patterns of expression of
cytochrome P450 genes in progression of hepatitis C virus-associated
hepatocellular carcinoma.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16077914&query_hl=18
Telomerase reverse
transcriptase mRNA expression in peripheral lymphocytes of patients with
chronic HBV and HCV infections. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108763&query_hl=18
Interferon-alpha suppresses liver cell proliferation in patients with
chronic hepatitis C virus infection. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108765&query_hl=18
Polymorphisms of the renin-angiotensin system and the severity of fibrosis
in chronic hepatitis C virus infection. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108768&query_hl=18
Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born
from HCV-infected women.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16023248&query_hl=18
Cytokine profile of
peripheral blood mononuclear cells from patients with different outcomes of
hepatitis C virus infection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108769&query_hl=18
GNB3 C825T polymorphism
and response to interferon-alfa/ribavirin treatment in patients with hepatitis
C virus genotype 1 (HCV-1) infection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16019105&query_hl=18
Accumulation of
8-nitroguanine in the liver of patients with chronic hepatitis C. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16023246&query_hl=18
Hepatitis C Virus Genotype
1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American
and White Patients. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107963&query_hl=18
Interdomain communication in hepatitis C virus polymerase abolished by small
molecule inhibitors bound to a novel allosteric site.
http://www.jbc.org/cgi/content/abstract/280/33/29765
Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis
C virus infected patients. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16202647&query_hl=5
Novel type I interferon
IL-28A suppresses hepatitis C viral RNA replication. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16146571&query_hl=18
Involvement of chemokines and type 1 cytokines in the pathogenesis of
hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16142759&query_hl=18
Suppression of hepatitis C
virus replication by cyclosporin a is mediated by blockade of cyclophilins.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16143140&query_hl=18
Mutations in the NS5B
region of the hepatitis C virus genome correlate with clinical outcomes of
interferon-alpha plus ribavirin combination therapy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16105128&query_hl=18
Broad Repertoire of the
CD4+ Th Cell Response in Spontaneously Controlled Hepatitis C Virus Infection
Includes Dominant and Highly Promiscuous Epitopes. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16148104&query_hl=18
Cryoglobulin-associated
uptake of hepatitis C virus into human hepatocytes. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16201113&query_hl=5
Positive selection of cytotoxic T lymphocyte escape variants during acute
hepatitis C virus infection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16114108&query_hl=18
In vitro studies of
cross-resistance mutations against two hepatitis C virus serine protease
inhibitors, VX-950 and BILN 2061. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16087668&query_hl=18
LKM1 autoantibodies in
chronic hepatitis C infection: a case of molecular mimicry? http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16037945&query_hl=18
Chronic liver injury in rat and man upregulates the novel enzyme angiotensin
converting enzyme II.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16166274&query_hl=18
The concentration of sFasL, ICE and IL-1beta in the serum and the liver
tissue of chronic HCV infected patients.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16201101&query_hl=5
HIV/HCV Coinfection
Transmission of Hepatitis
C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of
Pegylated Interferon and Ribavirin. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16123680&query_hl=18
Impact of hepatitis C
virus on immune restoration in HIV-infected patients who start highly active
antiretroviral therapy: a meta-analysis. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16080095&query_hl=18
Influence of Hepatitis C
Virus Infection on HIV-1 Disease Progression and Response to Highly Active
Antiretroviral Therapy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107951&query_hl=18
Impact of Chronic Viral Hepatitis on Health-Related Quality of Life in HIV:
Results from a Nationally Representative Sample.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16128943&query_hl=18
Prevalence of hepatitis B and C in pregnant women who are infected with
human immunodeficiency virus.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16157150&query_hl=18
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16163639&query_hl=18
Increased Hepatocyte Fas Expression and Apoptosis in HIV and Hepatitis C
Virus Coinfection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16206071&query_hl=5
Presence of Hepatitis C
Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16206070&query_hl=5
Slower fibrosis progression in HIV/HCV-coinfected patients with successful
HIV suppression using antiretroviral therapy.
Complementary and Alternative TherapiesTreatment of chronic
hepatitis C virus infection via antioxidants: results of a phase I clinical
trial.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16082287&query_hl=18
http://ict.sagepub.com/cgi/content/abstract/4/3/219
Miscellaneous Works
Susceptibility to
hepatitis A in patients with chronic liver disease due to hepatitis C virus
infection: missed opportunities for vaccination. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16104047&query_hl=18
Irritability rather than depression during interferon treatment is linked to
increased tryptophan catabolism. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16204437&query_hl=5
Description of a new hepatitis C risk assessment tool. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16186472&query_hl=18
Demographic, HIV risk
behavior, and health status characteristics of "crack" cocaine
injectors compared to other injection drug users in three New England cities. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16171952&query_hl=18
When Does Mother to Child Transmission of Hepatitis C Virus Occur? http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16121099&query_hl=18
Physical and psychosocial
contributors to quality of life in veterans with hepatitis C not on antiviral
therapy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16082286&query_hl=18
Ethical challenges in the
care of persons with hepatitis C infection: a pilot study to enhance informed
consent with veterans. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16145183&query_hl=18
Comparison of characteristics
of treated and non-treated patients with Hepatitis C infection.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16136612&query_hl=18
Changes in epidemiological patterns of HCV infection and their impact on
liver disease over the last 20 years in Greece.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108773&query_hl=18
Future trends of
HCV-related cirrhosis and hepatocellular carcinoma under the currently
available treatments.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16108772&query_hl=18